ANGEL-TNK — Intra-Arterial Tenecteplase After Successful EVT

1. Publication

• Title: Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial
• Acronym: ANGEL-TNK
• Year & Journal: JAMA, published 2025 (2025;334(7):582-591)
• Citation: Miao Z, Luo G, Song L, et al. Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial. JAMA. 2025;334(7):582-591. doi:10.1001/jama.2025.10800

2. Context & Rationale

Background: As with PEARL (this handbook), up to half of LVO stroke patients remain dependent/dead despite successful macrorecanalization, attributed partly to microcirculatory impairment. ANGEL-TNK specifically tested tenecteplase (rather than alteplase) as the adjunctive IA thrombolytic agent, using an rhTNK-tPA formulation with the same terminal amino acid sequence as that used in the TRACE trial series.

Research Question/Hypothesis: In anterior-circulation LVO stroke patients (4.5-24h from onset) with successful EVT reperfusion, does adjunctive IA tenecteplase improve 90-day excellent outcome (mRS 0-1) compared with standard medical management?

Why This Matters: Tests a different adjunctive thrombolytic agent (tenecteplase vs alteplase) within the same overall research question as PEARL, contributing to resolving agent-specific questions in this evolving field.

3. Design & Methods

• Study Type: Investigator-initiated, multicenter, randomized, open-label, blinded-endpoint, phase 3 trial
• Setting & Centers: 19 Chinese stroke centers (per secondary analysis reference; parent trial across multiple centers)
• Population:
• Inclusion: Anterior-circulation LVO stroke, 4.5-24h from symptom onset, successful reperfusion (eTICI ≥2b50) after EVT, confirmed by CTA/MRA imaging
• Exclusions: Not detailed in available trial text
• Intervention: IA tenecteplase (rhTNK-tPA)
• Comparator: Standard medical management
• Randomization: 1:1, up to 256 patients planned
• Blinding: Open-label treatment, assessor-blinded (blinded endpoint) evaluation
• Statistical Power & Follow-Up: Primary outcome: mRS 0-1 at 90 days. Primary safety outcome: symptomatic intracranial hemorrhage within 48h.

4. Key Results

Contrast with POST-TNK: A separate, similarly designed trial (POST-TNK, Huang et al., JAMA, January 2025) using a lower tenecteplase dose (0.0625 mg/kg, max 6.25mg) in 539 patients found NO significant difference in mRS 0-1 (49.1% vs 44.1%, adjusted RR not significant) — the contrast between ANGEL-TNK (positive) and POST-TNK (negative) may reflect dosing or population differences.

5. Internal Validity Assessment

• Randomization & Allocation: 1:1 randomization; specific concealment mechanics not detailed in available trial text.
• Protocol Adherence & Separation: Standardized IA tenecteplase dosing protocol; blinded-endpoint assessment.
• Blinding & Detection Bias: Open-label treatment (unavoidable for IA procedure) with blinded-endpoint evaluation — reduces detection bias.
• Missing Data & Sensitivity Analyses: Not detailed in available trial text.
• Overall Internal Validity Conclusion: Moderate-to-strong — blinded-endpoint assessment and a statistically significant primary result (P=0.02) with no safety penalty support the positive finding; however, the contrast with the similarly designed but negative POST-TNK trial (different tenecteplase dose) means dose-response and generalizability questions remain genuinely open.

6. External Validity Assessment

• Population Representativeness: Chinese population with anterior-circulation LVO and successful EVT reperfusion, extended window (4.5-24h) — relevant to real-world EVT-eligible populations including later-presenting patients.
• Practice Context: Requires EVT capability plus IA tenecteplase administration protocol; the specific rhTNK-tPA formulation used is a Chinese-manufactured product, potentially limiting direct international generalizability.
• Overall External Validity Conclusion: Moderate — relevant to Chinese and similar health systems with EVT capability; the formulation-specific and dose-specific nature of the positive result (contrasting with the negative POST-TNK using a different dose) limits confident generalization to other tenecteplase formulations/doses without confirmatory data.

7. Strengths & Limitations

Strengths:

• Blinded-endpoint assessment strengthens an open-label procedural trial
• Statistically significant benefit without excess symptomatic ICH or mortality difference
• Extended time window (4.5-24h) increases clinical relevance to later-presenting patients
• Contributes to a genuinely important, evolving evidence base on adjunctive IA thrombolysis agent selection

Limitations:

• Contrasts directly with the negative POST-TNK trial using a lower tenecteplase dose — an important, unresolved dose-response question
• Open-label treatment delivery
• Single-country (China), specific-formulation trial limits international generalizability

8. Interpretation & Practice Impact

• Clinical Implications: Supports considering adjunctive IA tenecteplase (at the ANGEL-TNK dose) after successful EVT reperfusion in similar populations — but the contrasting POST-TNK result at a different dose means dose selection appears to matter, and this should temper any assumption of a uniform "IA tenecteplase works" conclusion.
• Mechanistic Coherence: Consistent with the same microcirculatory-impairment rationale underlying PEARL (this handbook); the dose-dependent finding (positive at ANGEL-TNK's dose, negative at POST-TNK's lower dose) is mechanistically plausible for a thrombolytic agent.
• Systems-Level Takeaway: Per the 2025 ATLAS-ER meta-analysis, ANGEL-TNK and PEARL are both counted among the positive trials in this evolving field, while POST-TNK and POST-UK remain negative — dose and possibly TICI-grade subgroup (2b vs 2c-3) may be key moderators requiring further prospective clarification.

9. Controversies & Subsequent Evidence

• Editorial Commentary/Debates: Presented at the 2025 International Stroke Conference alongside PEARL, generating direct field discussion about the discordance with POST-TNK (published just weeks earlier, January 2025, and negative) — the AHA session report explicitly notes "the ANGEL-TNK findings contrast with those of the POST-TNK trial."
• Guideline Integration: Contributes to the 2025 ATLAS-ER meta-analysis (6 RCTs) and the Lancet Neurology's "Progress in ischaemic stroke research in 2025" review, both synthesizing this genuinely mixed, actively evolving evidence landscape for adjunctive IA thrombolysis after EVT.

10. Summary & Executive Takeaway

Summary: ANGEL-TNK randomized Chinese patients with anterior-circulation LVO stroke and successful EVT reperfusion (4.5-24h window) to adjunctive IA tenecteplase or standard medical management. mRS 0-1 at 90 days was significantly higher with IA tenecteplase (40.5% vs 26.4%, P=0.02), with no significant difference in symptomatic ICH or mortality — contrasting with the negative POST-TNK trial using a lower tenecteplase dose.

Overall Takeaway: ANGEL-TNK adds positive evidence for adjunctive IA tenecteplase after successful EVT reperfusion, but its direct contrast with the negative, lower-dose POST-TNK trial highlights that dose selection is likely a critical, still-unresolved variable in this genuinely mixed and actively evolving evidence landscape — alongside PEARL, 2025 marks meaningful progress but not final resolution of the adjunctive-IA-thrombolysis question.

11. Bibliography

• Huang J, Yang J, Liu C, et al. Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial. JAMA. 2025. doi:10.1001/jama.2024.23466
• Writing Committee for the PEARL Investigators. PEARL Trial. JAMA. 2025;334(19):1728-1739.